

19. (Amended) The method of claim[s] 1 or] 2, wherein the cell is contacted with the [hedgehog antagonist] organic molecule *in vivo*.
20. (Amended) The method of claim 1 [or 2], wherein the [hedgehog antagonist] organic molecule is administered as part of a therapeutic or cosmetic application.
21. (Amended) The method of claim 1 [19 or 20], wherein the [hedgehog antagonist] organic molecule is administered to treat a condition selected from [the group consisting of] regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth muscle, regulation of lung, liver and other organs arising from the [primitive] primitive gut, regulation of hematopoietic function, and regulation of skin and hair growth[, etc.]
22. (Amended) The method of [any of] claim[s] 1[-7], wherein the [hedgehog antagonist] organic molecule is administered [applied] as a topical formulation to skin [in order] to inhibit aberrant proliferation of epithelial cells.
23. (Amended) The method of claim 1 [any of claims 1-17 or 22], wherein the [hedgehog antagonist] organic molecule is administered to the patient to inhibit growth of a basal cell carcinoma.
25. (Amended) [The preparation of claim 24,] A pharmaceutical preparation formulated for topical application, comprising a purified organic molecule having a molecular weight less than 750 amu, wherein the organic molecule interacts with *smoothened* or a complex comprising *smoothened* and lessens the severity of a *hedgehog* gain-of-function, *patched* loss-of-function, or *smoothened* gain-of-function phenotype.

REMARKS


This submission is responsive to the Examiner's determination that the previously filed preliminary amendment did not comply with the rules for making amendments. The present paper presents the same amendments in compliant format.

Upon entry of the foregoing amendment, claims 1, 2, 15-23, 25, and 27-37 constitute the pending claims in the present application. The Examiner may address any questions raised by this submission to the undersigned at 617-951-7000. Should any fee be required for timely consideration of this submission, Applicants hereby request that the fee be charged to **Deposit Account No. 18-1945**.

Respectfully Submitted,

Date: February 8, 2002

Customer No: 28120
Docketing Specialist
Ropes & Gray
One International Place
Boston, MA 02110
Phone: 617-951-7000
Fax: 617-951-7050



David P. Halstead, Ph.D.
Reg. No. 44,735